{
  "_metadata": {
    "version": "2.1",
    "ticker": "ARGX",
    "asset_name": "Efgartigimod",
    "extraction_date": "2026-02-11",
    "source_id": "argx_corporate_2026"
  },
  "asset": {
    "name": "Efgartigimod (VYVGART / VYVGART Hytrulo)",
    "company": "argenx SE",
    "ticker": "ARGX",
    "stage": "Approved (gMG, CIDP) / Phase 3 (Ocular MG, Myositis, ITP, Sjogren's) / Registrational (Seronegative gMG, Graves')",
    "modality": "Fc fragment (antibody fragment)",
    "ownership": "Wholly-owned",
    "one_liner": "Efgartigimod is the first-in-class FcRn-blocking Fc fragment approved for gMG and CIDP, with $4.2B in 2025 net sales and 6 upcoming Phase 3 readouts across autoimmune indications.",
    "commercial_metrics": {
      "us_prescribers": ">4,700 (20% YoY increase)",
      "prescriber_trend": "New prescriber and patient growth continuing",
      "mg_position": "#1 prescribed biologic \u2014 drove 60% growth in overall MG biologics share",
      "cidp_status": "Achieved blockbuster status as of 3Q 2025",
      "mg_patient_source": "70% of new patients coming directly from orals (earlier line adoption)",
      "formulations": [
        "IV (efgartigimod alfa-fcab)",
        "SC vial (efgartigimod + hyaluronidase)",
        "SC PFS (approved US, EU)",
        "Autoinjector (est. 2027)"
      ],
      "source": {
        "id": "argx_jpm_2026_slides",
        "slide": 11,
        "verified": true
      }
    }
  },
  "target": {
    "name": "FcRn",
    "full_name": "Neonatal Fc Receptor",
    "class": "Receptor",
    "pathway": "IgG recycling / FcRn-mediated IgG homeostasis",
    "biology": {
      "simple_explanation": "FcRn is a receptor that rescues IgG antibodies from degradation, keeping their levels high in the blood. By blocking FcRn, efgartigimod accelerates breakdown of pathogenic IgG autoantibodies, reducing the autoimmune attack on the body's tissues.",
      "pathway_detail": null,
      "downstream_effects": [
        "Reduction of pathogenic IgG autoantibodies",
        "Reduction of total IgG levels"
      ]
    },
    "why_good_target": {
      "clinical_validation": "VYVGART approved in gMG (AChR+) and CIDP; ~19K patients treated globally; #1 prescribed biologic in MG driving 60% growth in overall MG biologics share",
      "genetic_validation": {
        "gain_of_function": null,
        "loss_of_function": null
      },
      "source": {
        "id": "argx_corporate_2026",
        "slide": 11,
        "verified": false
      }
    }
  },
  "mechanism": {
    "type": "FcRn blocker (Fc fragment)",
    "how_it_works": "Efgartigimod is an engineered Fc fragment that binds FcRn with high affinity, blocking its ability to recycle IgG antibodies, accelerating IgG degradation including pathogenic autoantibodies.",
    "differentiation": "First-in-class Fc fragment; first and only FcRn blocker approved in MG; available as IV (VYVGART) and SC with hyaluronidase (VYVGART Hytrulo PFS); autoinjector estimated 2027",
    "source": {
      "id": "argx_corporate_2026",
      "slide": 20,
      "verified": false
    }
  },
  "regulatory": {
    "designations": [
      "Approved: AChR-Ab+ gMG (US, EU, China, Canada, Japan)",
      "Approved: CIDP (US, Japan, China, EU)",
      "Approved: ITP (Japan)",
      "VYVGART SC PFS approved in US and EU",
      "sBLA for seronegative gMG \u2014 FDA Priority Review, PDUFA May 10, 2026",
      "UplighTED TED program discontinued for futility (Dec 2025)"
    ],
    "planned_pathway": "Seronegative gMG approval expected May 2026 \u2192 broadest MG label. Ocular MG (ADAPT-OCULUS 1Q26). ITP US submission after ADVANCE-NEXT (4Q26). Myositis (ALKIVIA 3Q26). Sjogren's (UNITY 2H27). Autoinjector launch ~2027."
  },
  "partnership": {
    "_note": "No co-development partner. Delivery technology partnerships only.",
    "partner": null,
    "territory": null,
    "economics": null,
    "delivery_partnerships": [
      {
        "partner": "Halozyme",
        "technology": "Hyaluronidase for SC formulation (PFS approved)",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 16,
          "verified": false
        }
      },
      {
        "partner": "Ypsomed",
        "technology": "Autoinjector (estimated 2027)",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 16,
          "verified": false
        }
      }
    ]
  },
  "pharmacology": {
    "pk_parameters": {
      "half_life": {
        "value": null,
        "population": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "cmax": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "auc": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "tmax": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "bioavailability": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "volume_of_distribution": {
        "value": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      }
    },
    "dose_response": {
      "doses_tested": null,
      "dose_rationale": null,
      "exposure_response": null,
      "recommended_dose": {
        "dose": null,
        "rationale": null,
        "source": {
          "id": "argx_corporate_2026",
          "slide": null,
          "verified": false
        }
      },
      "by_dose": null
    },
    "target_engagement": {
      "metric": "IgG reduction from baseline (%)",
      "by_dose": [
        {
          "dose": null,
          "engagement": "IgG reduction curve shown (slide 21) \u2014 efgartigimod achieves cyclical ~60-70% IgG reduction from baseline oscillating over 140-day period; no numeric axis values provided",
          "compartment": "blood",
          "source": {
            "id": "argx_corporate_2026",
            "slide": 21,
            "verified": false
          }
        }
      ]
    },
    "pk_summary": "PK/PD curve on slide 21 shows efgartigimod has cyclical IgG reduction pattern (oscillating between ~-20% and ~-70% from baseline) compared with ARGX-213 which achieves sustained ~-75-80% reduction. No numeric PK values provided."
  },
  "indications": {
    "approved": [
      {
        "indication": "Generalized MG (AChR-Ab+)",
        "status": "Approved globally",
        "regions": "US, EU, Japan, China, Canada"
      },
      {
        "indication": "CIDP",
        "status": "Approved",
        "regions": "US, Japan, China, EU"
      },
      {
        "indication": "ITP",
        "status": "Approved",
        "regions": "Japan only"
      }
    ],
    "registrational": [
      {
        "indication": "Seronegative gMG (MuSK+, LRP4+, triple sero-)",
        "status": "sBLA filed, PDUFA May 10, 2026",
        "trial": "ADAPT-SERON"
      },
      {
        "indication": "Ocular MG",
        "status": "Phase 3, readout 1Q 2026",
        "trial": "ADAPT-OCULUS"
      },
      {
        "indication": "Myositis (IMNM, ASyS, DM)",
        "status": "Phase 3, readout 3Q 2026",
        "trial": "ALKIVIA"
      },
      {
        "indication": "ITP (US)",
        "status": "Phase 3, readout 4Q 2026",
        "trial": "ADVANCE-NEXT"
      },
      {
        "indication": "Sjogren's Disease",
        "status": "Phase 3, readout 2H 2027",
        "trial": "UNITY"
      },
      {
        "indication": "Graves' Disease",
        "status": "Registrational study initiating 2026",
        "trial": null
      }
    ],
    "proof_of_concept": [
      {
        "indication": "Systemic Sclerosis",
        "status": "PoC ongoing, readout 2H 2026"
      },
      {
        "indication": "Antibody Mediated Rejection",
        "status": "PoC ongoing, readout 2027"
      },
      {
        "indication": "Autoimmune Encephalitis",
        "status": "PoC ongoing"
      }
    ],
    "discontinued": [
      {
        "indication": "Thyroid Eye Disease",
        "status": "Discontinued for futility Dec 2025",
        "trial": "UplighTED"
      }
    ],
    "total_indications_studied": "15+ severe autoimmune diseases",
    "source": {
      "id": "argx_jpm_2026_slides",
      "slide": 23,
      "verified": true
    }
  },
  "clinical_data": {
    "trials": [
      {
        "name": "ADAPT Oculus",
        "nct_id": null,
        "phase": "Phase 3",
        "status": "Readout expected 1Q 2026",
        "design": null,
        "enrollment": null,
        "arms": null,
        "primary_endpoint": {
          "name": "MGII (novel primary endpoint)",
          "definition": null,
          "result": null,
          "source": {
            "id": "argx_corporate_2026",
            "slide": 26,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "prior_evidence": "ADAPT ocular domain data and real-world case reports",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 26,
          "verified": false
        }
      },
      {
        "name": "ALKIVIA",
        "nct_id": null,
        "phase": "Phase 3",
        "status": "Readout expected 3Q 2026",
        "design": null,
        "enrollment": null,
        "arms": null,
        "primary_endpoint": {
          "name": "TIS (Total Improvement Score) composite",
          "definition": null,
          "result": null,
          "source": {
            "id": "argx_corporate_2026",
            "slide": 26,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "prior_evidence": "ALKIVIA PoC: significant improvement in muscle strength (TIS) in Phase 2",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 26,
          "verified": false
        }
      },
      {
        "name": "ADVANCE NEXT",
        "nct_id": null,
        "phase": "Phase 3",
        "status": "Readout expected 4Q 2026",
        "design": null,
        "enrollment": null,
        "arms": null,
        "primary_endpoint": {
          "name": "Cumulative platelet count",
          "definition": null,
          "result": null,
          "source": {
            "id": "argx_corporate_2026",
            "slide": 26,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "prior_evidence": "ADVANCE Phase 3 IV and real world data from Japan",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 26,
          "verified": false
        }
      },
      {
        "name": "UNITY",
        "nct_id": null,
        "phase": "Phase 3",
        "status": "Readout expected 2H 2027",
        "design": null,
        "enrollment": null,
        "arms": null,
        "primary_endpoint": {
          "name": "Not specified (described as 'challenging primary endpoint')",
          "definition": null,
          "result": null,
          "source": {
            "id": "argx_corporate_2026",
            "slide": 26,
            "verified": false
          }
        },
        "secondary_endpoints": null,
        "biomarkers": null,
        "safety": null,
        "prior_evidence": "RHO and DAHLIAS PoC: reductions in systemic disease activity in Phase 2",
        "source": {
          "id": "argx_corporate_2026",
          "slide": 26,
          "verified": false
        }
      },
      {
        "name": "UplighTED Phase 3 (TED) \u2014 DISCONTINUED",
        "nct_id": "NCT06307626 / NCT06307613",
        "phase": "Phase 3",
        "status": "Discontinued for futility (Dec 15, 2025)",
        "design": "Two parallel Phase 3 randomized, double-masked, placebo-controlled, multicenter studies. 2:1 randomization (efgartigimod PH20 SC vs placebo PH20 SC). N=123 per study. Adults with active, moderate-to-severe TED associated with Graves' disease or Hashimoto's thyroiditis.",
        "enrollment": "123 per study (246 total across two studies)",
        "primary_endpoint": {
          "name": "Proptosis responders at Week 24",
          "definition": "Percentage of participants who were proptosis responders at Week 24",
          "result": "FAILED \u2014 IDMC recommended stopping for futility after pre-specified interim analysis. Treatment unlikely to meet primary endpoint.",
          "source": {
            "id": "argx_uplighted_dec2025",
            "slide": null,
            "verified": true
          }
        },
        "secondary_endpoints": [
          {
            "name": "Change in proptosis measurement from baseline to Week 24",
            "result": null
          },
          {
            "name": "Change in GO-QoL total score from baseline to Week 24",
            "result": null
          },
          {
            "name": "Percentage with diplopia resolution at Week 24",
            "result": null
          }
        ],
        "safety": {
          "summary": "Favorable safety and tolerability profile. No new safety signals identified.",
          "source": {
            "id": "argx_uplighted_dec2025",
            "slide": null,
            "verified": true
          }
        },
        "source": {
          "id": "argx_uplighted_dec2025",
          "slide": null,
          "verified": true
        }
      },
      {
        "name": "ADAPT-SERON (Seronegative gMG)",
        "nct_id": null,
        "phase": "Phase 3",
        "status": "Completed \u2014 positive. sBLA accepted by FDA with Priority Review. PDUFA May 10, 2026.",
        "design": "Randomized, double-blind, placebo-controlled, multi-center. Part A: 1:1 randomization to 4 weekly IV infusions of efgartigimod or placebo, 5-week follow-up. Part B: open-label extension with fixed 2 cycles then flexible dosing based on clinical status. Sites across North America, Europe, China, Middle East.",
        "enrollment": "119 (AChR-Ab seronegative gMG: MuSK+, LRP4+, and triple seronegative subtypes)",
        "arms": [
          {
            "name": "Efgartigimod IV",
            "n": null,
            "description": "4 once-weekly infusions"
          },
          {
            "name": "Placebo",
            "n": null,
            "description": "4 once-weekly infusions"
          }
        ],
        "inclusion": "Confirmed MG diagnosis by independent expert panel. MG-ADL total score >= 5. Stable dose of >= 1 gMG treatment (AChEIs, corticosteroids, or nonsteroidal ISTs). AChR-Ab seronegative (MuSK+, LRP4+, or triple seronegative).",
        "primary_endpoint": {
          "name": "MG-ADL total score change from baseline to Day 29 (Part A)",
          "definition": "MG-ADL is a validated measure evaluating functional impact on daily activities: speaking, chewing, swallowing, breathing, limb strength",
          "result": "MET \u2014 statistically significant improvement (p=0.0068). Mean improvement of 3.35 points in MG-ADL total score at Week 4 (clinically meaningful).",
          "source": {
            "id": "argx_adapt_seron_pr_2026",
            "slide": null,
            "verified": true
          }
        },
        "secondary_endpoints": [
          {
            "name": "QMG score",
            "result": "Improvements observed across subsequent treatment cycles in overall population and all subgroups"
          },
          {
            "name": "MG-QoL 15r",
            "result": null
          },
          {
            "name": "MGC",
            "result": null
          },
          {
            "name": "EQ-5D-5L VAS",
            "result": null
          }
        ],
        "subgroup_analyses": [
          {
            "subgroup": "MuSK+ patients",
            "result": "Improvements in MG-ADL and QMG observed"
          },
          {
            "subgroup": "LRP4+ patients",
            "result": "Improvements in MG-ADL and QMG observed. No prior approved treatments for this subtype."
          },
          {
            "subgroup": "Triple seronegative patients",
            "result": "Improvements in MG-ADL and QMG observed. Historically excluded from studies. Higher disease burden and unmet need. No prior approved treatments."
          }
        ],
        "safety": {
          "summary": "Well-tolerated. Safety profile consistent with established VYVGART profile in AChR-Ab seropositive gMG and other indications. No new safety concerns identified.",
          "common_aes": [
            "Respiratory tract infection",
            "Headache",
            "Urinary tract infection"
          ],
          "serious_warnings": [
            "Infections (UTI, respiratory)",
            "Hypersensitivity reactions",
            "Infusion-related reactions"
          ],
          "source": {
            "id": "argx_adapt_seron_pr_2026",
            "slide": null,
            "verified": true
          }
        },
        "source": {
          "id": "argx_adapt_seron_pr_2026",
          "slide": null,
          "verified": true
        }
      }
    ],
    "de_risking_context": {
      "ocular_mg": "Supported by ADAPT ocular domain data + real-world case reports. Novel MGII primary endpoint.",
      "myositis": "ALKIVIA supported by Phase 2 showing significant improvement in muscle strength (TIS). Heterogeneous disease with TIS composite primary endpoint.",
      "itp": "Supported by ADVANCE Phase 3 IV data + real-world data from Japan. Cumulative platelet count primary endpoint. Targets difficult-to-treat patients.",
      "mmn": "EMPASSION supported by Phase 2 proof of concept (ARDA study showed sustained improved grip strength). Head-to-head vs IVIg.",
      "sjogrens": "Supported by RHO and DAHLIAS Phase 2 proof of concept showing reductions in systemic disease activity. Challenging primary endpoint.",
      "source": {
        "id": "argx_jpm_2026_slides",
        "slide": 26,
        "verified": true
      }
    }
  },
  "differentiation_claims": [
    {
      "claim": "#1 prescribed biologic in MG, driving 60% growth in overall MG biologics share",
      "evidence_level": "management_claim",
      "caveat": "Based on argenx market research as of 4Q 2025",
      "source": {
        "id": "argx_corporate_2026",
        "slide": 11,
        "verified": false
      }
    },
    {
      "claim": "First-in-class Fc fragment with 15+ indications",
      "evidence_level": "management_claim",
      "caveat": null,
      "source": {
        "id": "argx_corporate_2026",
        "slide": 20,
        "verified": false
      }
    },
    {
      "claim": "First and only development program in Ocular MG",
      "evidence_level": "management_claim",
      "caveat": null,
      "source": {
        "id": "argx_corporate_2026",
        "slide": 12,
        "verified": false
      }
    },
    {
      "claim": "70% of new MG patients coming directly from orals (earlier line adoption)",
      "evidence_level": "management_claim",
      "caveat": "argenx market research",
      "source": {
        "id": "argx_corporate_2026",
        "slide": 11,
        "verified": false
      }
    }
  ],
  "competitive_landscape": {
    "competitors": null,
    "_note": "No specific competitor drugs named in this presentation"
  },
  "ip_landscape": {
    "composition_of_matter": {
      "patent_expiry": null,
      "source": {
        "id": "argx_corporate_2026",
        "slide": null,
        "verified": false
      }
    },
    "method_of_use": {
      "patent_expiry": null,
      "source": {
        "id": "argx_corporate_2026",
        "slide": null,
        "verified": false
      }
    },
    "regulatory_exclusivity": {
      "type": null,
      "expiry": null
    },
    "freedom_to_operate": null
  },
  "market_opportunity": {
    "tam": "gMG: 60K US patients by 2030 (17K at launch); CIDP: 42K diagnosed (12K at launch); ITP: significant Japan market; Myositis, Sjogren's, Ocular MG, seronegative gMG all expansion",
    "patient_population": "~19,000 patients on VYVGART globally (Jan 2026). 15+ severe autoimmune diseases being studied.",
    "current_revenue": "$4.15B FY2025 product net sales (+90% YoY). Q4 2025: $1.29B. Q3 2025: $1.13B.",
    "us_prescribers": ">4,700 US prescribers (20% YoY increase)",
    "pricing_benchmark": null,
    "peak_sales_estimate": "UBS estimates $6.1B VYVGART sales in FY2026 ($4.6B MG + $1.5B CIDP). William Blair modeled $550M peak TED (now removed).",
    "unmet_need": "70% of new MG patients coming directly from orals (earlier treatment paradigm adoption). 12,000 CIDP patients remain inadequately controlled on SOC in US.",
    "source": {
      "id": "argx_jpm_jan2026",
      "slide": null,
      "verified": false
    }
  },
  "catalysts": [
    {
      "event": "Seronegative gMG PDUFA decision date",
      "timing": "May 10, 2026",
      "importance": "critical",
      "what_to_watch": "FDA Priority Review. ADAPT-SERON met primary (p=0.0068, MG-ADL -3.35pts). If approved: broadest MG label, adds ~20% of gMG population (MuSK+, LRP4+, triple seronegative). First-ever treatment for LRP4+ and triple seronegative patients. Launch expected by end 2026.",
      "bull_scenario": "Approval expands TAM by ~11K US patients. No competition in seronegative space. Cements VYVGART as definitive MG treatment across all subtypes.",
      "bear_scenario": "Unexpected FDA concerns or CRL, though unlikely given Priority Review and clean data."
    },
    {
      "event": "Ocular MG Phase 3 readout (ADAPT Oculus)",
      "timing": "1Q 2026",
      "importance": "critical",
      "what_to_watch": "MGII novel primary endpoint; first and only development in Ocular MG",
      "bull_scenario": "Positive data adds ~7K patients to US addressable market",
      "bear_scenario": "Novel endpoint may not capture clinically meaningful benefit"
    },
    {
      "event": "AChR- gMG (seronegative) approval decision",
      "timing": "By end of 2026",
      "importance": "critical",
      "what_to_watch": "Broadest MG label (MuSK+, LRP4+, triple seronegative)",
      "bull_scenario": "Adds ~11K seronegative patients to US addressable market",
      "bear_scenario": "Regulatory delays or additional data requirements"
    },
    {
      "event": "Myositis Phase 3 readout (ALKIVIA)",
      "timing": "3Q 2026",
      "importance": "critical",
      "what_to_watch": "TIS composite endpoint; 70K US prevalence",
      "bull_scenario": "Opens rheumatology market with no targeted therapies",
      "bear_scenario": "Disease heterogeneity may lead to mixed results"
    },
    {
      "event": "ITP Phase 3 readout (ADVANCE NEXT)",
      "timing": "4Q 2026",
      "importance": "critical",
      "what_to_watch": "Cumulative platelet count in difficult-to-treat patients",
      "bull_scenario": "Validates broad ITP utility",
      "bear_scenario": "Difficult-to-treat population may limit effect size"
    },
    {
      "event": "Sjogren's Phase 3 readout (UNITY)",
      "timing": "2H 2027",
      "importance": "high",
      "what_to_watch": "Challenging primary endpoint; 330K US prevalence",
      "bull_scenario": "Opens largest indication by patient population",
      "bear_scenario": "Historically difficult endpoint in Sjogren's trials"
    },
    {
      "event": "UplighTED Phase 3 TED \u2014 DISCONTINUED for futility",
      "timing": "Dec 15, 2025 (completed \u2014 FAILED)",
      "importance": "high",
      "what_to_watch": "IDMC stopped trials at interim for futility. Proptosis endpoint not met. Removes ~$550M peak sales. Data at future meeting.",
      "bull_scenario": null,
      "bear_scenario": "Signals FcRn mechanism may not work in all IgG-mediated diseases; raises questions about other expansion indications"
    },
    {
      "event": "ADAPT-Forward combination study (efgartigimod + empasiprubart) in AChR+ gMG",
      "timing": "Ongoing (started 2025)",
      "importance": "medium",
      "what_to_watch": "First combination study; could show deeper efficacy and differentiate from single-agent FcRn competitors"
    }
  ],
  "investment_analysis": {
    "probability_of_success": null,
    "key_risks": [
      "Novel/composite primary endpoints across multiple Phase 3 trials",
      "ITP trial in difficult-to-treat patients may limit generalizability",
      "FcRn class competition",
      "Rheumatology commercial expansion requires new prescriber base"
    ],
    "bull_case": [
      {
        "thesis": "Market-leading franchise with $4.2B revenue and 90% YoY growth",
        "evidence": "FY 2025 product net sales (slide 7)",
        "confidence": "high"
      },
      {
        "thesis": "Label expansion to 60K US addressable MG patients by 2030",
        "evidence": "US addressable patient waterfall (slide 12)",
        "confidence": "medium"
      },
      {
        "thesis": "CIDP blockbuster validates multi-indication strategy",
        "evidence": "Blockbuster status as of 3Q 2025 (slide 11)",
        "confidence": "high"
      }
    ],
    "bear_case": [
      {
        "thesis": "Novel Phase 3 endpoints create binary risk across 4 readouts in 2026",
        "evidence": "MGII, TIS, cumulative platelet, challenging endpoint (slide 26)",
        "confidence": "medium"
      },
      {
        "thesis": "Rheumatology expansion requires new commercial infrastructure",
        "evidence": "Current prescriber base is neurology-focused (slide 11)",
        "confidence": "medium"
      }
    ],
    "key_debates": [
      {
        "question": "Will the MGII novel primary endpoint succeed in Ocular MG?",
        "bull_view": "ADAPT ocular domain data and real-world case reports support endpoint",
        "bear_view": "Novel endpoints carry inherent risk",
        "what_resolves_it": "1Q 2026 Phase 3 readout"
      }
    ]
  },
  "_extraction_quality": {
    "completeness_score": "medium",
    "missing_critical_fields": [
      "PK parameters",
      "Dosing regimen",
      "Safety data",
      "Trial enrollment/arms",
      "NCT IDs",
      "Competitive landscape",
      "IP/patents",
      "Regulatory designations"
    ],
    "recommended_supplementary_sources": [
      "argenx 20-F for financials and IP",
      "ClinicalTrials.gov for trial details",
      "VYVGART prescribing information",
      "ADAPT/ADAPT+ published papers"
    ]
  }
}